Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) EBITDA (2020 - 2025)

Bioventus (BVS) has disclosed EBITDA for 6 consecutive years, with $12.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 272.22% year-over-year to $12.5 million, compared with a TTM value of $23.4 million through Dec 2025, up 153.27%, and an annual FY2025 reading of $23.4 million, up 145.69% over the prior year.
  • EBITDA was $12.5 million for Q4 2025 at Bioventus, up from $4.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $32.0 million in Q4 2023 and bottomed at -$138.6 million in Q2 2023.
  • Average EBITDA over 5 years is -$12.5 million, with a median of -$6.1 million recorded in 2024.
  • The sharpest move saw EBITDA tumbled 2334.84% in 2022, then skyrocketed 272.22% in 2025.
  • Year by year, EBITDA stood at -$8.8 million in 2021, then plummeted by 248.55% to -$30.7 million in 2022, then soared by 204.26% to $32.0 million in 2023, then tumbled by 122.74% to -$7.3 million in 2024, then surged by 272.22% to $12.5 million in 2025.
  • Business Quant data shows EBITDA for BVS at $12.5 million in Q4 2025, $4.2 million in Q3 2025, and $8.7 million in Q2 2025.